CR
Corbus Pharmaceuticals Holdings, Inc.
CRBP · NASDAQ
$7.48 +2.33% (+$0.17)
1M -23.98%
Market Cap $134.5M
P/E Ratio -
Div. Yield -
ROE 87.05%
Bulios Fair Price
$8.25
10.3% upside
Current Price
$7.48
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CRBP is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 1.32x
EV/FFO N/A
P/E N/A
Growth
100 /100
Growing Book val. growth 64.74%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 80.25%
ROIC 100.35%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 5.71x
Debt/Equity 0.04x
Debt/Assets N/A
Stability
10 /100
Unstable Profitable years 0
Beta 2.64x
EPS volatility 62.35%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CRBP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Yuval Cohen
Employees
36
Headquarters
Norwood
Upcoming events
11 NOV
Earnings
Upcoming earnings report